Compare Ascendis Pharma A/S (ASND) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Skyworks Solutions Inc — how do they compare? Ascendis Pharma A/S trades at $263.88 (market cap $17.74B), while Skyworks Solutions Inc trades at $58.63 (market cap $9.08B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Skyworks Solutions Inc pays a 4.7% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | SWKS | |
|---|---|---|
Market Cap | $17.74B | $9.08B |
Sector | Health | Technology |
52-Week High | $277.18 | $83.40 |
52-Week Low | $163.32 | $52.50 |
Enterprise Value | $18.11B | $8.85B |
Dividend Yield | — | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SWKS trades at $60.36, up 0.68% on the day, with a bearish technical signal but bullish oscillators. The company reported Q1 2026 EPS of $1.15, beating estimates, and maintains a dividend. Revenue has trended down from $5.5B in 2022 to $4.1B in 2025, though net income margin remains positive at 8.93%. Recent news highlights potential in smartphone chips and AI infrastructure.
The outlook is mixed: strong analyst buy consensus (60%) and a $72.56 price target suggest upside, but declining revenue, legal investigations, and a bearish technical trend pose risks. The stock's valuation at a P/E of 25.16 appears reasonable if growth stabilizes, but investor caution is warranted amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
